Navigation Links
MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
Date:7/24/2008

NEW YORK, July 24 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced results of a Phase 2 clinical trial involving 37 patients who completed a 48-week, U.S. multi-center, open-label efficacy and safety study of EcoNail, a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). The composite primary efficacy endpoint of the trial was "complete cure" defined as negative mycology (negative fungal culture and negative KOH) and clear nail (as determined by expert panel review of clinical photographs). EcoNail is the company's patented, topically-applied lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA(R).

A protocol-mandated, external expert panel assessed clinical photographs of 37 onychomycosis patients who completed 48 weeks of EcoNail treatment. The panel observed that 24 patients (65%) showed evidence of clinical improvement, defined in the protocol as an increase in uninvolved (clear) nail area. While none of the 37 patients reached all criteria of the composite primary endpoint, the consensus judgment of the panel was that 15 of 37 patients (41%) demonstrated significant (greater than or equal to 25%) clinical improvement. All patients had fungal culture-proven nail infections at entry, but after 48 weeks of once-daily treatment with EcoNail, 100% of patients had cultures that were negative for dermatophyte growth. Eight of the 37 patients (22%) achieved the secondary endpoint of negative mycology (negative fugal culture plus negative KOH evaluation) at 48 weeks. The panel observed no signs of local irritation related to the once-daily EcoNail treatment. During the trial, no patient required interruption of dosing due to local intolerability. Through 56 weeks of observation, no cutaneous adverse events were attributed by the investigators to EcoNail.

The laboratory of Boni Elewski, MD, Professor of Dermatology at the University of Alabama-Birmingham, perf
'/>"/>

SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
4. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
5. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
6. Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... TUCSON, Ariz. , Aug. 20, 2014 /PRNewswire/ ... of the  Roche  Group, today announced that its ... been CE marked in the European Union for ... specimens. The system, consisting of VENTANA Virtuoso software ... the VENTANA iScan HT slide scanner, provides automated ...
(Date:8/20/2014)... Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces that ... has received Chinese FDA (CFDA) approval and has ... into the China domestic ... distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., ... FDA approved and China CFDA certified oral solid ...
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that a ... catalogue: The Market for Medical Devices ... The European, Middle Eastern and African markets represent ... part of its coverage, this study: The Market ... EMEA medical device markets and estimates markets for ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5
... 19 Stallergenes S.A.,today announced that the Paul ... biological products, has approved its application for a,pediatric ... Grasses,sublingual tablets for desensitization to grass pollens. , ... adults was granted on June 24, 2008.,Oralair(R) Grasses ...
... the international,investment house specialising in medical sciences, said ... pioneering stem cell treatments if it is,to remain ... Professor Sir Christopher Evans, founder ... plc has received approval from the UK,Medicines and ...
Cached Medicine Technology:STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany 2STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany 3STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany 4UK Must Maintain its Momentum in Stem Cell Expertise 2
(Date:8/20/2014)... Top10BestSEOHosting.com is a website dedicated to providing ... is headed by a team of experts and ... information and factual studies about the newest hosting ... , Recently, Top10BestSEOHosting.com has compared many Linux ... and Bluehost are the most recommended suppliers for ...
(Date:8/20/2014)... Today, Zane Benefits, the #1 ... a new eBook, Affordable Care Act 101. , ... feel uncertain about how the ACA impacts their ... line. , The new eBook outlines key ACA ... their upcoming health insurance decisions. , Read the ...
(Date:8/20/2014)... -- A group representing U.S. obstetricians is calling for ... According to the American College of Obstetricians and Gynecologists ... the safety and effectiveness of flu vaccination during pregnancy. ... be particularly dangerous to pregnant women, as it can ... Riley, chair of the college,s Immunization Expert Work Group, ...
(Date:8/20/2014)... than 42 percent of women underwent breast reconstruction ... associated with foregoing reconstruction included being black, having ... Author: Monica Morrow, M.D., of the Memorial Sloan ... Background: The Women,s Health and Cancer Rights Act ... following a mastectomy. Still, most women who undergo ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hundreds of ... behalf of women who were allegedly injured due to ... in New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... on August 15, 2014, the Court has established procedures ... Mirena lawsuits that are part of the proceeding’s initial ...
Breaking Medicine News(10 mins):Health News:New Reviews For Linux Web Hosting Suppliers Announced By Top10BestSEOHosting.com 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4
... , THURSDAY, Nov. 24 (HealthDay News) -- Black Friday, the ... the quest as it is about getting good deals, according ... the Black Friday adventure phenomenon, the more fun you,re likely ... professor at Wake Forest University, said in a university news ...
... THURSDAY, Nov. 24 (HealthDay News) -- The holiday season can ... there are a number of things they can do to ... because many traditional holiday foods contain such allergens as wheat, ... news release from the American College of Allergy, Asthma and ...
... or processed meat is positively associated with aggressive prostate cancer, ... journal PLoS ONE . The research ... Francisco, also found that the correlation was primarily driven by ... done. They suggest that this result, which was ...
... HealthDay Reporter , WEDNESDAY, Nov. 23 (HealthDay ... not an asthma diagnosis are often prescribed inhaled steroid ... those medications on an as-needed basis instead of every ... wheezing in young children, and the treatment for some ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, Nov. ... that the drug company Merck will pay $950 million to ... which was pulled from the market in 2004 after studies ... stroke. Merck will pay $321.6 million in criminal ...
... the numbers indicate that improvements are possible," says Hyland at ... in Boston, USA, 234 million major surgical procedures are conducted ... human beings undergoes a major surgical procedure each year. ... According to the WHO, serious complications occur in three to ...
Cached Medicine News:Health News:Allergy Sufferers Should Prepare for Holiday Triggers 2Health News:Intermittent Steroid Use Called OK for Wheezing Preschoolers 2Health News:Intermittent Steroid Use Called OK for Wheezing Preschoolers 3Health News:Merck to Pay $950M to Settle Probe of Vioxx Marketing 2Health News:Merck to Pay $950M to Settle Probe of Vioxx Marketing 3Health News:Creating safer surgery to save more lives 2Health News:Creating safer surgery to save more lives 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: